

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 61264

**Title:** Scoparone inhibits pancreatic cancer through the PI3K/Akt signaling pathway

**Reviewer's code:** 05266762

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** Germany

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-03-04

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-03-08 00:17

**Reviewer performed review:** 2021-03-31 13:45

**Review time:** 23 Days and 13 Hours

|                                 |   |
|---------------------------------|---|
| <b>Scientific quality</b>       | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good<br><input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| <b>Language quality</b>         | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| <b>Conclusion</b>               | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority)<br><input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |
| <b>Re-review</b>                | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |
| <b>Peer-reviewer statements</b> | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous<br>Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

Pancreatic cancer is the seventh leading cause of death worldwide with an increasing trend. At present, surgical resection is the primary treatment method for pancreatic cancer. However, only few patients are eligible for surgical resection because of late diagnosis. Pancreatic cancer has a strong tendency to metastasize and a high recurrence rate following surgery. Scoparone belongs to the coumarin class of natural organic compounds, and is widely used in the prevention and treatment of neonatal jaundice. Scoparone may inhibit the proliferation of prostate cancer cells by directly interfering with the transcription of signal transducer and activator of transcription 3. In this study, the antitumor activity of scoparone on pancreatic cancer cells was evaluated. And, the authors investigated the molecular mechanism of action, providing evidence of a potential drug or adjuvant for pancreatic cancer treatment. The manuscript is very well written. The research methods are detail and reasonable. The pancreatic cancer cell culture, and the cell viability assay were analyzed. The results are very interesting, and are well discussed with updated references. I recommend to accept this manuscript for publication after minor language editing. Thank you.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 61264

**Title:** Scoparone inhibits pancreatic cancer through the PI3K/Akt signaling pathway

**Reviewer's code:** 05261059

**Position:** Peer Reviewer

**Academic degree:** FEBG, MD, PhD

**Professional title:** Assistant Professor, Senior Lecturer

**Reviewer's Country/Territory:** United Kingdom

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-03-04

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-03-08 00:17

**Reviewer performed review:** 2021-03-31 13:48

**Review time:** 23 Days and 13 Hours

|                                 |   |
|---------------------------------|---|
| <b>Scientific quality</b>       | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good<br><input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| <b>Language quality</b>         | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| <b>Conclusion</b>               | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority)<br><input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |
| <b>Re-review</b>                | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |
| <b>Peer-reviewer statements</b> | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous<br>Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |

#### **SPECIFIC COMMENTS TO AUTHORS**

This is an interesting study about the Scoparone in the treatment of pancreatic cancer. The manuscript is very good. Only the figures are not in a high resolution. Please check and update the images.